Aigen Investment Management LP Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aigen Investment Management LP acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 723 shares of the biopharmaceutical company’s stock, valued at approximately $760,000.

A number of other institutional investors and hedge funds have also bought and sold shares of REGN. Sachetta LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $26,000. Crewe Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $28,000. Finally, Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $821.00 on Wednesday. The company has a 50 day simple moving average of $1,014.52 and a two-hundred day simple moving average of $1,037.74. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $784.96 and a fifty-two week high of $1,211.20. The company has a market capitalization of $90.22 billion, a price-to-earnings ratio of 20.32, a P/E/G ratio of 3.12 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 7.48% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have commented on REGN. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,107.25.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.